Please assess the completion status of the following clinical trial:

Trial Title: Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between the ages of 21 and 85 years~2. Diagnosed with symptomatic persistent AF Documentation of history of AF for at least 6 months AF not spontaneously converting to sinus rhythm, persisting for ≥7 days Sinus rhythm after cardioversion is NOT exclusion, provided that≥2 episodes of persistent AF occurred in the previous 6 months~3. Resistant or intolerant to at least one class I, II, or III anti arrhythmic drugs (AAD)~4. Patients deemed candidates for radio frequency(RF) ablation of AF~5. Able and willing to comply with pre-, post-, and follow-up requirements.~Exclusion Criteria:~1. Patients with previous PVAI procedure or left heart ablation procedure.~2. Left atrial thrombus.~3. LA diameter greater than 65 mm on long axis parasternal view, or left atrial volume more than 200 cc by MRI or CT.~4. Left ventricular ejection fraction \< 30%.~5. Cardiac surgery within the previous 180 days.~6. Expecting cardiac transplantation or other cardiac surgery within 180 days.~7. Coronary percutaneous transluminal coronary angioplasty (PTCA)/stenting within the previous 90 days.~8. Documented history of a thrombi-embolic event within the previous 90 days.~9. Diagnosed atrial myxoma.~10. Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.~11. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment~12. Women who are pregnant.~13. Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC \> 11. 000 mm3) for which antibiotics have been or will be prescribed.~14. Creatinine\> 2. 5 mg/dl (or \> 221 μmol/L, except for patients in dialysis).~15. Unstable angina.~16. Myocardial infarction within the previous 60 days.~17. History of blood clotting or bleeding abnormalities.~18. Contraindication to anticoagulation.~19. Contraindication to computed tomography or MRI procedures.~20. Life expectancy less than 1 year.~21. Uncontrolled heart failure.~22. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.~23. Presence of a condition that precludes vascular access.~24. Institute for Natural Resources (INR) greater than 3. 5 within 24 hours of procedure.~25. Cannot be removed from antiarrhythmic drugs for reasons other than AF.~26. Unwilling or unable to provide informed consent.~27. Current reported alcoholism.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Standard Catheter Ablation Patient Group (Type: ACTIVE_COMPARATOR): Patients will have a standard procedure ablation
- Vein of Marshall and Standar procedure (Type: ACTIVE_COMPARATOR): The doctor will inject Ethanol through a balloon catheter into the VOM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete